Kura Oncology Announces Presentation of Preliminary Clinical Data for Tipifarnib in HRAS Mutant Squamous Cell Carcinomas of the Head and Neck at TAT 2017

LA JOLLA, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced an oral presentation for its lead product candidate, tipifarnib, at the 15th International Congress on Targeted Anticancer Therapies (TAT 2017), taking place March 6-8, 2017 in Paris, France. The presentation will feature clinical data from the first stage of Kura Oncology’s tipifarnib Phase 2 program in HRAS mutant tumors.

Date & Time: March 6, 2017, 2:45 p.m. – 3:00 p.m. CET
Title of Presentation: Preliminary evidence of clinical activity with tipifarnib in squamous cell carcinomas of the head & neck (SCCHN) with HRAS mutations
Presenter: Alan L. Ho, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
Session: Plenary Session 3: Phase 1 Studies – Completed or in progress (miscellaneous drugs & targets)

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The pipeline includes KO-947, an ERK inhibitor, and KO-539, an inhibitor of the menin-MLL protein-protein interactions. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.


Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932

Mark Corbae
Vice President
Canale Communications
(619) 849-5375